Navigation Links
AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Date:11/12/2012

sis. All three trials were conducted in patients with non-cancer pain and documented OIC, who require daily opioid therapy.

Enrolment is complete for the open-label, randomized, 52-week long-term safety trial (KODIAC-08) and the trial is expected to be completed by Q1 2013.

Naloxegol is currently considered a Schedule II controlled substance by the US Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone. AstraZeneca has conducted the studies necessary to evaluate the abuse potential and dependence-producing properties of naloxegol in support of obtaining decontrol. A petition for the decontrol of naloxegol was submitted to the DEA in March 2012 and subsequently accepted for review. Commercialisation and launch in the US will be subject to both FDA approval and DEA schedule determination.

Nektar to Host Conference Call with Investors and AnalystsNektar Therapeutics (Nasdaq: NKTR) will host an investor and analyst conference call today to discuss these results.  The call will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard Time (PST).
A link to the live conference call webcast is accessible from the home page of the Nektar website: http://www.nektar.com.

To access the conference call live by telephone, please follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 70465377 (Nektar Therapeutics is the host)

About Naloxegol
Naloxegol is a peripherally-acting mu-opioid receptor antagonist being investigated for the treatment of constipation (opioid-induced constipation or OIC) as a side effect of prescription opioid pain medicines.

Top-line results of the Phase II study of naloxegol (formerly NKTR-118) were previously presented at the American College of Gastroenterology Annual Clinical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
4. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
5. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
6. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
8. Boston Childrens Hospital announces international genomics competition winner
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
11. AMRI Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 3 Waters Corporation (NYSE: WAT ... Mass Spectrometry (ASMS) presented Prof. Alison Ashcroft of ... Hites Award for Outstanding Research Publication in the ... (JASMS). Prof. Ashcroft,s paper titled, Monitoring Copopulated ...
... Million Bridge Facility to Haemacure , , ... (NASDAQ: ANPI , TSX: ANP), a ... the completion of a collaboration transaction with Haemacure ... certain of Haemacure,s proprietary fibrin and thrombin technologies, ...
... Regulation with GP531 Improves the Heart,s Pumping Function in Dogs ... June 3 PeriCor Therapeutics, Inc. announced today that positive ... in a poster presentation by Hani N. Sabbah, Ph.D., at ... study was funded by PeriCor Therapeutics, Inc. and conducted by ...
Cached Biology Technology:First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes 2First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes 3Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation 2Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation 3Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation 4Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation 5Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation 6PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice 2PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice 3
(Date:12/17/2014)... , Dec. 15, 2014 The ... make it easier to detect and prevent counterfeit ... Today the agency started performing an in-house ... will validate the authenticity of purchased microcircuits while ... new quality control measures will be conducted at ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... mothers who have allergies or asthma have an increased risk of ... before 6 months of age. This is shown in a ... (MoBa) at the Norwegian Institute of Public Health (NIPH). ... from MoBa. Approximately 25 percent of these children took part ...
... is available in French . , ... Management, the private bankers Lombard Odier Darier Hentsch & ... at EPFL dedicated to sustainable development. The chair is ... fundamental and social sciences in the environmental domain. ...
... professor of molecular medicine Victor R. Ambros, PhD, ... world of investigation into developmental biology, will receive ... the most prestigious in science. Dr. Ambros shares ... of genetics at Harvard Medical School, with whom ...
Cached Biology News:Possible link between baby swimming and breathing problems in children 2EPFL Research Day 2008, in the presence of Al Gore 2EPFL Research Day 2008, in the presence of Al Gore 3UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 2UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 3
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
... 200 g of lyophilized peptide derived from ... acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide ... of Cayman's EP1 receptor polyclonal antibody (Catalog ... conjunction with this antibody to block protein-antibody ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Biology Products: